- Home
- PIII vs PRTG Comparison
PIII vs PRTG Comparison
Compare PIII & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- PRTG
- Stock Information
- Founded
- PIII 2015
- PRTG 1973
- Country
- PIII United States
- PRTG British Virgin Islands
- Employees
- PIII N/A
- PRTG N/A
- Industry
- PIII Medical/Nursing Services
- PRTG Oil & Gas Production
- Sector
- PIII Health Care
- PRTG Energy
- Exchange
- PIII Nasdaq
- PRTG Nasdaq
- Market Cap
- PIII 20.8M
- PRTG 17.7M
- IPO Year
- PIII N/A
- PRTG N/A
- Fundamental
- Price
- PIII $7.27
- PRTG $5.73
- Analyst Decision
- PIII Buy
- PRTG
- Analyst Count
- PIII 2
- PRTG 0
- Target Price
- PIII $16.25
- PRTG N/A
- AVG Volume (30 Days)
- PIII 4.7K
- PRTG 19.8K
- Earning Date
- PIII 08-06-2025
- PRTG 08-26-2025
- Dividend Yield
- PIII N/A
- PRTG N/A
- EPS Growth
- PIII N/A
- PRTG N/A
- EPS
- PIII N/A
- PRTG N/A
- Revenue
- PIII $1,485,192,000.00
- PRTG N/A
- Revenue This Year
- PIII N/A
- PRTG N/A
- Revenue Next Year
- PIII $7.92
- PRTG N/A
- P/E Ratio
- PIII N/A
- PRTG N/A
- Revenue Growth
- PIII 9.79
- PRTG N/A
- 52 Week Low
- PIII $6.00
- PRTG $2.10
- 52 Week High
- PIII $32.54
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- PIII 62.71
- PRTG 42.85
- Support Level
- PIII $6.30
- PRTG $5.50
- Resistance Level
- PIII $7.51
- PRTG $6.20
- Average True Range (ATR)
- PIII 0.36
- PRTG 0.40
- MACD
- PIII 0.15
- PRTG 0.06
- Stochastic Oscillator
- PIII 84.11
- PRTG 27.06
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.